Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma

Cancer

Volumn 120, Issue 24, 2014, Pages 3902-3913

  Zaidi, Ali H ^a   Gopalakrishnan, Vanathi ^b   Kasi, Pashtoon M ^b   Zeng, Xuemei ^c   Malhotra, Usha ^d   Balasubramanian, Jeya ^b   Visweswaran, Shyam ^b   Sun, Mai ^c   Flint, Melanie S ^c   Davison, Jon M ^c   Hood, Brian L ^c   Conrads, Thomas P ^c   Bergman, Jacques J ^e   Bigbee, William L ^c   Jobe, Blair A ^a  

^a ALLEGHENY HEALTH NETWORK   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Early detection; Esophageal adenocarcinoma; Monitoring; Protein; Serum

Indexed keywords

BIGLYCAN; CALGRANULIN B; CALPHOBINDIN II; MYELOPEROXIDASE; RESISTIN; BGN PROTEIN, HUMAN; PEROXIDASE; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; BARRETT ESOPHAGUS; BAYESIAN RULE LEARNING PREDICTIVE MODEL; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; FALSE POSITIVE RESULT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MATHEMATICAL MODEL; NON INVASIVE MEASUREMENT; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PROBABILITY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; TANDEM MASS SPECTROMETRY; TREND STUDY; VALIDATION PROCESS; ADENOCARCINOMA; BIOLOGICAL MODEL; BLOOD; EARLY DIAGNOSIS; ESOPHAGEAL NEOPLASMS; EVALUATION STUDY; PROCEDURES;

ADENOCARCINOMA; ANNEXIN A6; BARRETT ESOPHAGUS; BIGLYCAN; CALGRANULIN B; CHROMATOGRAPHY, LIQUID; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; PEROXIDASE; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84919347969     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28963     Document Type: Article

References (38)

1. Dubecz A, Solymosi N, Stadlhuber RJ, Schweigert M, Stein HJ, Peters JH. Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first century? A SEER database analysis [published online ahead of print November 15, 2013]. J Gastrointest Surg. 2013.
2. Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol. 2010; 105: 1490-1502.
3. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013; 19: 5598-5606.
4. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013; 310: 627-636.
5. Spechler SJ. Screening and surveillance for complications related to gastroesophageal reflux disease. Am J Med. 2001; 111(suppl 8A): 130S-136S.
6. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998; 93: 1028-1032.
7. Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002; 97: 1888-1895.
8. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut. 2001; 48: 304-309.
9. Reavis KM, Morris CD, Gopal DV, Hunter JG, Jobe BA. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms. Ann Surg. 2004; 239: 849-856; discussion 856-858.
10. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001; 96: 2839-2848.
11. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007; 4: 207-214.
12. Teng PN, Rungruang BJ, Hood BL, et al. Assessment of buffer systems for harvesting proteins from tissue interstitial fluid for proteomic analysis. J Proteome Res. 2010; 9: 4161-4169.
13. Gopalakrishnan V, Lustgarten JL, Visweswaran S, Cooper GF. Bayesian rule learning for biomedical data mining. Bioinformatics. 2010; 26: 668-675.
14. Ryberg H, An J, Darko S, et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve. 2010; 42: 104-111.
15. Bigbee WL, Gopalakrishnan V, Weissfeld JL, et al. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol. 2012; 7: 698-708.
16. Sokal RR, Rohlf FJ. Biometry: The Principles and Practice of Statistics in Biological Research. New York: WH Freeman; 1995.
17. Neapolitan RE. Learning Bayesian Networks. Upper Saddle River, NJ: Prentice Hall; 2004.
18. Cooper GF, Herskovits E. A Bayesian method for the induction of probabilistic networks from data. Machine Learning. 1992; 9: 309-347.
19. Lustgarten JL. A Bayesian Rule Generation Framework for"Omic" Biomedical Data Analysis: Pittsburgh, PA: University of Pittsburgh; 2009.
20. Lustgarten JL, Visweswaran S, Gopalakrishnan V, Cooper GF. Application of an efficient Bayesian discretization method to biomedical data. BMC Bioinformatics. 2011; 12: 309.
21. Lustgarten JL, Visweswaran S, Grover H, Gopalakrishnan V. An evaluation of discretization methods for learning rules from biomedical datasets. In: Doble M, ed. International Conference on Bioinformatics, Computational Biology, Genomics and Chemoinformatics (BCBGC-08). International Society for Research and Technology/Curran Associates, Inc. (Proceedings.com); 2008: 527-532.
22. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1: 845-867.
23. Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology. 1992; 102(4 pt 1): 1220-1228.
24. van Dekken H, Hop WC, Tilanus HW, et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol. 2008; 130: 745-753.
25. Washington K, Chiappori A, Hamilton K, et al. Expression of betacatenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol. 1998; 11: 805-813.
26. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene. 1996; 13: 1867-1873.
27. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000; 92: 1316-1321.
28. Ong CA, Lao-Sirieix P, Fitzgerald RC. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol. 2010; 16: 5669-5681.
29. Castillo-Tong DC, Pils D, Heinze G, et al. Association of myeloperoxidase with ovarian cancer. Tumour Biol. 2014; 35: 141-148.
30. Fan NJ, Gao CF, Wang CS, et al. Identification of the upregulation of TP-alpha, collagen alpha-1(VI) chain, and S100A9 in esophageal squamous cell carcinoma by a proteomic method. J Proteomics. 2012; 75: 3977-3986.
31. Zhu YH, Yang F, Zhang SS, Zeng TT, Xie X, Guan XY. High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2013; 6: 2497-2505.
32. Lomnytska MI, Becker S, Bodin I, et al. Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value. Br J Cancer. 2011; 104: 110-119.
33. Sakwe AM, Koumangoye R, Guillory B, Ochieng J. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions. Exp Cell Res. 2011; 317: 823-837.
34. Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer. 2000; 89: 1413-1417.
35. Ishikawa N, Takano A, Yasui W, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 2007; 67: 11601-11611.
36. Wang JS, Varro A, Lightdale CJ, et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol. 2010; 105: 1039-1045.
37. Zhao J, Chang AC, Li C, et al. Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using twodimensional liquid mass mapping. Mol Cell Proteomics. 2007; 6: 987-999.
38. Stingl C, van Vilsteren FG, Guzel C, et al. Reproducibility of protein identification of selected cell types in Barrett's esophagus analyzed by combining laser-capture microdissection and mass spectrometry. J Proteome Res. 2011; 10: 288-298.